High Neutrophil-Lymphocyte Ratio, Platelet-Lymphocyte Ratio and Low Lymphocyte Levels Are Correlated With Worse Pathological Complete Response Rates

Karakaya, Serdar; Karadağ, İbrahim; Yılmaz, Mehmet Emin; Öksüzoğlu, Ömür Berna

doi:10.7759/cureus.22972

Cited by 4 publications

(4 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar to our study, Karakaya et al determined that low NLR and PLR levels were associated with high pCR among 227 patients with rectal cancer who received nCRT. NLR and PLR were independent predictive markers for pCR 12 . In a retrospective study for rectal cancer (n=176), NLR < 2.0 and PLR < 133.4 were significantly associated with a good tumor response, and patients with NLR < 2.0 had a significantly better five-year DFS and overall survival (OS) rate compared to those with NLR ⩾2.0 16 .…”

Section: Discussionmentioning

confidence: 85%

See 1 more Smart Citation

A new prognostic index associated with pathological complete response in rectal cancer

Yetisir

Büyükşimşek

Oğul

et al. 2023

Cukurova Medical Journal

View full text Add to dashboard Cite

Purpose: Approximately half of rectal cancer cases are diagnosed at a locally advanced stage. It is important to identify biomarkers that can predict pathological complete response in patients undergoing surgery following neoadjuvant chemoradiotherapy. Materials and Methods: This retrospective study included 205 patients with locally advanced rectal cancer who underwent surgery and adjuvant chemotherapy following neoadjuvant chemoradiotherapy. Inflammatory biomarkers were assayed in the complete blood count before neoadjuvant therapy. Results: A pathological complete response was detected in 20.5% of the patients. The neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and pan-immune inflammation value were significantly lower in the pathological complete response (+) group than in the pathological complete response (-) group. The cut-off of the pan-immune inflammation value was ≤ 331.2, and this parameter had the best diagnostic performance of 90.4%. Conclusion: Neoadjuvant chemoradiotherapy followed by surgery and adjuvant chemotherapy remains the standard treatment approach for rectal cancer. Since pathological complete response improves oncological outcomes, it is important to identify biomarkers that can predict pathological complete response in rectal cancer

show abstract

Section: Discussionmentioning

confidence: 85%

“…The sample of the study was calculated using the G*Power 3.1.9. 12 , the medium effect size was accepted as 0.8 difference in our study. The alpha significance level was calculated as 0.05, and the sample size in 95% Power was calculated as a total of 205 patients, 163 in Group 1 and 42 in Group 2.…”

Section: Patients and Study Designmentioning

confidence: 79%

A new prognostic index associated with pathological complete response in rectal cancer

Yetisir

Büyükşimşek

Oğul

et al. 2023

Cukurova Medical Journal

View full text Add to dashboard Cite

show abstract

“…Therefore, an elevated NLR may serve as an independent prognostic factor for OS owing to the counts of increased neutrophils and reduced lymphocytes. Serdar Karakaya et al reported that a high NLR was correlated with worse pathological complete response rates in locally advanced rectal cancer and emerged as independent predictive marker [27]. Yu Tung Lo et al found that post-steroid NLR could predict OS in primary central nervous system lymphoma [28].…”

Section: Discussionmentioning

confidence: 99%

Prognostic value of the modified systemic inflammation score in non-small-cell lung cancer with brain metastasis

et al. 2022

View full text Add to dashboard Cite

Background Brain metastases (BM) from non-small-cell lung cancer (NSCLC) is the most common brain malignancy. Systemic inflammation biomarkers have recently been evaluated as prognosis indicators in several tumors. The combination of these markers has not been evaluated in NSCLC with BM yet. Here, we explored the predictive value of pretreatment inflammatory biomarkers and established a novel, clinically applicable prognostic index for NSCLC patients with BM. Methods A retrospective investigation of 951 NSCLC patients newly diagnosed with BM at Sun Yat-sen University Cancer Center was conducted. We randomly divided patients into a training cohort (n = 674) or validation cohort (n = 277). Receiver operating characteristic (ROC) curve analysis was carried out to obtain the optimal cut-off values of pretreatment systemic inflammatory indexes. The associations between serum biomarkers and overall survival (OS) were analyzed by Kaplan–Meier curves and Cox proportional models. The resulting prediction model has been externally verified through the validation cohort. Results The optimal cut-off value of the neutrophil–lymphocyte ratio (NLR) in predicting OS was 4.71, while the clinical standard of 40 mg/L was chosen as the optimal cut-off value of albumin. Univariate and multivariate analyses revealed that patients receiving local treatment, chemotherapy, a NLR < 4.71 and albumin ≥ 40 mg/l independently predicted improved survival. We combined the two inflammatory indexes (NLR and albumin level) to establish the modified systemic inflammation score (mSIS) which divides patients into low risk, medium risk or high-risk groups. The 1-year OS rates of three groups were 59.7%, 40.5% and 29.4%, respectively in the training cohort. The same result was verified in the validation cohort with the 1-year OS rates 69.7%, 47.0% and 7.7%, respectively. The mSIS exhibited better discrimination power than the American Joint Committee on Cancer’s (AJCC) 7th T + N staging system in the training cohort (Harrell’s concordance index (C-index): 0.744 vs 0.502, P < 0.05), and the discrimination was also superior to that of AJCC’s 7th T + N staging system in the validation cohort (C-index: 0.724 vs 0.527, P < 0.05). The 1-year and 2-year OS rates of the AUC also exhibited superior survival predictive ability to that of the AJCC’s 7th T + N staging system in NSCLC patients with BM. Conclusion The pretreatment mSIS may be an independent prognostic factor for OS in NSCLC patients with BM and warrants further research.

show abstract

“…The systemic inflammatory response (SIR) has been a widely emphasized factor associated with cancer development, progression, and metastasis. The association of various biomarkers, such as neutrophil-tolymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), modified Glasgow prognostic score (mGPS), and systemic immune-inflammation index (SII), with SIR and oncological outcomes has been studied in several cancer types, including LARC [10][11][12]. A number of studies have also demonstrated a relationship between SIR and radiotherapy (RT) response [13,14].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Predictive and Prognostic Importance of Lung Immune Prognostic Index in Locally Advanced Rectal Cancer Patients Treated With Neoadjuvant Chemoradiotherapy

Arıkan¹,

Alkış²,

Işık³

et al. 2023

Cureus

View full text Add to dashboard Cite

Objective: The systemic inflammatory response (SIR) is known as an important factor associated with tumorigenesis and tumor progression, and can be reflected by inflammatory markers. One of the markers that reflect this is the lung immune prognostic index (LIPI). It is based on a derived neutrophil-to-lymphocyte ratio (dNLR) and lactate dehydrogenase (LDH) level. We aimed to investigate the significance of LIPI in locally advanced rectal cancer (LARC) patients treated with neoadjuvant chemoradiotherapy (NACRT). Methods: In this retrospective study, we stratified the patients according to LIPI score as good LIPI and intermediate (int)/poor LIPI. According to pathological response to NACRT, we divided the patients into two groups as those with complete response (CR) or near-CR, and those with partial response (PR) or poor/no response. We classified CR and near-CR as good response. We evaluated the predictive and prognostic significance of LIPI for NACRT response, disease-free survival (DFS), and overall survival (OS) by univariate and multivariate analyses. Results: We included 137 patients in the results, with 72 (52.6%) having good LIPI and 65 (47.4%) having int/poor LIPI. The median follow-up period was 44.7 months (range: 10-105 months). Thirteen patients (18.0%) in the good LIPI group and 22 patients (34.0%) in the int/poor LIPI group achieved good response. In multivariate analysis, we found only the LIPI score as an independent risk factor (hazard ratio (HR): 2.4, p = 0.04) for NACRT response. Median DFS was 89.2 months (95% CI: 11.4-167.0) in the int/poor LIPI group; however, the DFS of all study populations and patients in the good LIPI group did not reach the median value. In multivariate analysis for DFS, we identified abdominoperineal resection (APR) (HR: 2.21, p = 0.02), presence of tumor deposit (HR: 2.96, p = 0.003), and int/poor LIPI score (HR: 2.07, p = 0.02) as separate risk variables. OS of all study populations and the patients in the LIPI groups did not reach the median value. In multivariate analysis for OS, we identified APR (HR: 2.74, p = 0.02), surgical margin positivity (HR: 12.94, p < 0.001), and adjuvant CT (HR: 0.20, p = 0.002) as separate risk variables for OS. Conclusion: This is the first study investigating the predictive and prognostic significance of LIPI in LARC patients treated with NACRT. The results revealed that int/poor LIPI was associated with a higher rate of good response but shorter DFS compared to good LIPI. The baseline LIPI score serves as an easily accessible and useful prognostic index, and it has significant potential for making appropriate treatment decisions in LARC.

show abstract

High Neutrophil-Lymphocyte Ratio, Platelet-Lymphocyte Ratio and Low Lymphocyte Levels Are Correlated With Worse Pathological Complete Response Rates

Cited by 4 publications

References 34 publications

A new prognostic index associated with pathological complete response in rectal cancer

A new prognostic index associated with pathological complete response in rectal cancer

Prognostic value of the modified systemic inflammation score in non-small-cell lung cancer with brain metastasis

Evaluation of Predictive and Prognostic Importance of Lung Immune Prognostic Index in Locally Advanced Rectal Cancer Patients Treated With Neoadjuvant Chemoradiotherapy

Contact Info

Product

Resources

About